CYP2C9 gene segment containing 373C>T mutation, encoded protein segment and application of CYP2C9 gene segment

A technology of nucleic acid fragments and mutation sites, applied in the field of biology, can solve problems such as differences in drug efficacy, insufficiency, drug toxicity and side effects, etc.
CN112458158AInactive Publication Date: 2021-03-09杨杰孚 +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
杨杰孚
Publication Date
2021-03-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a CYP2C9 gene segment containing the 373C>T mutation, a coded protein segment and an application of the CYP2C9 gene segment, belongs to the field of biology, and relates to single base mutations. More specifically, the invention relates to a mutation site, corresponding to a 373th site of SEQ ID NO.2, of a CYP2C9 gene, a nucleic acid fragment containing the mutation site, aprotein fragment coded by the nucleic acid fragment, and an application of the nucleic acid fragment, wherein the site is mutated from wild type C to T. The mutant CYP2C9 protein, namely R125C, caused by the single base mutation has lower metabolic activity of drugs compared than wild type CYP2C9 protein, and therefore the guiding significance is provided for the medication of individuals carrying the mutation site.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biology and relates to a single base mutation; more specifically, the invention relates to a single base mutation of CYP2C9 gene. Background technique

[0002] CYP2C9 is the most important member of the CYP2C subfamily of the cytochrome P450 enzyme family, accounting for about 20% of the total CYP enzymes in human liver microsomes. About 10-16% of commonly used clinical drugs are oxidatively metabolized by CYP2C9, mainly including tolbutamide, S-warfarin, phenytoin, glipizide, glibenclamide, toratimide, losartan, urethane Medications such as besartan and many NSAIDs (eg, ibuprofen, lornoxicam, diclofenac, and naproxen) (see References 1-5).

[0003] The CYP2C9 gene is highly polymorphic. According to current clinical research, this polymorphism of CYP2C9 gene is the main reason for the great difference in CYP2C9 enzyme activity among individuals, so it can cause great differences in drug efficacy among individual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More